Clinical Trial

PM534 Administered Intravenously to Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goals of this trial are to identify the dose limiting toxicities, to determine the maximum tolerated dose and the recommended dose of PM534 in patients with advanced solid tumors. All Patients will receive PM534 via intravenous.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-18; most recent amendment 2025-08-18.
Trial Details
NCT Number NCT05835609
Lead Sponsor PharmaMar
Conditions Patients With Advanced Solid Tumors
Enrollment 30 participants
Start Date 2022-12-23
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-08-22